TScan Therapeutics (TCRX) Net Cash Flow Growth (3y) (2023 - 2026)
TScan Therapeutics (TCRX) Net Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.65 Bn | 466.85 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.09 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.74 Bn | 50.56 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - | - |
| 10 | TScan Therapeutics | 100.19 Mn | -27.87 Mn | - | 0.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.10% |
| Dec 31, 2025 | 0.35% |
| Sep 30, 2025 | -78.77% |
| Jun 30, 2025 | 44.28% |
| Mar 31, 2025 | -6.12% |
| Dec 31, 2024 | 68.30% |
| Sep 30, 2024 | -50.85% |
| Jun 30, 2024 | 105.21% |
| Mar 31, 2024 | -56.47% |
| Dec 31, 2023 | -35.92% |
| Sep 30, 2023 | -95.95% |